Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors

2002181 citationsJournal Articlebronze Open Access

Authors

Sebastian Schneeweiß · Brigham and Women's Hospital

Alexander M. Walker · Harvard University

Robert J. Glynn · Brigham and Women's Hospital

Malcolm Maclure · Harvard University

Colin R. Dormuth · Ministry of Health

Stephen B. Soumerai · Harvard Pilgrim Health Care

Abstract

We found little evidence that when reference pricing for ACE inhibitors was introduced in British Columbia, patients stopped treatment for hypertension or that health care utilization and costs increased.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Medication Adherence and Compliance

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 346, Issue 11, pp. 822-829

DOI: 10.1056/nejmsa003087

Field-Weighted Citation Impact: 60.64